# CPG10101 Combination Therapy For The Treatment Of Hepatitis C In Relapsed Hepatitis C Virus (HCV) Subjects

> **NCT00142103** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 91 (actual)

## Conditions studied

- Hepatitis, Chronic Active

## Interventions

- **DRUG:** CPG10101
- **DRUG:** CPG10101
- **DRUG:** CPG10101
- **DRUG:** CPG10101
- **DRUG:** Control
- **DRUG:** CPG10101

## Key facts

- **NCT ID:** NCT00142103
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-09
- **Primary completion:** 2007-02
- **Final completion:** 2007-02
- **Target enrollment:** 91 (ACTUAL)
- **Last updated:** 2011-05-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00142103

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00142103, "CPG10101 Combination Therapy For The Treatment Of Hepatitis C In Relapsed Hepatitis C Virus (HCV) Subjects". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00142103. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*